Metoprolol extended release pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers
Pharmacokinetics of Metoprolol Extended Release: Key Parameters
Metoprolol extended-release (ER) formulations are designed to provide a controlled and sustained release of the drug, resulting in more stable plasma concentrations over a 24-hour period compared to immediate-release (IR) formulations. The main pharmacokinetic parameters of interest include the time to maximum concentration (Tmax), maximum plasma concentration (Cmax), area under the concentration-time curve (AUC), and relative bioavailability.
Tmax, Cmax, and AUC in Metoprolol ER
Studies comparing different ER formulations of metoprolol have shown that while the AUC and Cmax are generally similar between brand and generic products, the Tmax can vary significantly. For example, one study found that the brand formulation had a mean Tmax of 6.1 hours, while two generics had Tmax values of 3.5 and 9.6 hours, respectively, despite similar AUC and Cmax values. This suggests that while overall exposure is comparable, the rate at which the drug reaches peak concentration can differ between products, potentially affecting clinical outcomes related to autonomic balance over the dosing interval .
Influence of Release Rate and Formulation
The rate at which metoprolol is released from ER formulations directly influences its absorption and pharmacokinetics. Faster release rates result in shorter Tmax and higher Cmax, while slower release rates prolong Tmax and may reduce Cmax. However, the extent of absorption (AUC) is less affected by release rate, provided the formulation allows for complete absorption in the gastrointestinal tract. Some studies have shown that very slow-release formulations may have reduced bioavailability, possibly due to incomplete absorption or increased first-pass metabolism Mistry2002Sandberg1991.
Bioequivalence and Food Effects
Multiple studies have demonstrated that different ER formulations, including generics, are bioequivalent to reference products under both fasting and fed conditions, with 90% confidence intervals for AUC and Cmax falling within the accepted bioequivalence range (80-125%). This has been confirmed in both single-dose and steady-state studies, and across different populations Zhao-Yi2006Yang2023. Food intake does not significantly alter the pharmacokinetics of metoprolol ER, supporting its use as a once-daily medication regardless of meals .
Impact of Formulation Variability
Changes in the formulation, particularly in the release-controlling excipients, can affect the dissolution rate and, consequently, the pharmacokinetics of metoprolol ER. Modeling studies have shown that significant increases in the release rate constant can lead to non-bioequivalence in pharmacokinetics, especially in Cmax, but these differences may not always translate into clinically meaningful changes in pharmacodynamic outcomes such as exercise-induced heart rate reduction Kim2019Basu2019. The properties of the release-controlling polymer are critical for ensuring consistent in vitro dissolution and in vivo absorption .
Comparison with Immediate-Release Formulations
Compared to IR formulations, metoprolol ER provides more even plasma concentrations, with less pronounced peaks and troughs. This results in a more consistent β1-blockade over 24 hours, which is beneficial for conditions like heart failure and hypertension. The ER formulation also shows a more uniform suppression of heart rate and better tolerability in clinical studies Wikstrand2003Karlson2013.
In Vivo Release and Absorption
Advanced drug delivery systems, such as programmable capsules, have demonstrated that in vivo drug release profiles for metoprolol ER closely match the intended release patterns, with relative bioavailability around 85%, similar to other ER formulations. This confirms the reliability of ER formulations in delivering predictable pharmacokinetic profiles .
Conclusion
Metoprolol extended-release formulations are engineered to provide stable and predictable pharmacokinetics, with consistent AUC and Cmax across different products and minimal impact from food intake. While differences in Tmax and release rate can occur between formulations, these generally do not affect overall drug exposure or clinical efficacy. The choice of release-controlling excipients is crucial for maintaining bioequivalence and therapeutic consistency among ER products Mosley2022Mistry2002Wikstrand2003+7 MORE.
Sources and full results
Most relevant research papers on this topic